Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





COVID-19 Vaccine Safety Technical (VaST) Work Group Report, June 28, 2021										Related Pages
										The Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Safety Technical (VaST) Work Group has reviewed post-authorization vaccine safety data weekly or biweekly since the start of the U.S. COVID-19 vaccination program in December 2020. Updates of VaST activities and VaST assessments of safety data were presented at ACIP meetings on January 27, March 1, April 14, April 23, May 12, and June 23; ACIP meetings are open to the public. In lieu of presentations at ACIP meetings, VaST reports from March 29, May 17, and May 24 have been posted on the ACIP website.
During the VaST meeting on June 28, 2021, members reviewed data on reports of Guillain-Barré syndrome (GBS) among persons who received COVID-19 vaccination. The data are from several sources, including passive surveillance in the Vaccine Adverse Event Reporting System (VAERS) and active surveillance in the Vaccine Safety Datalink (VSD) and the Department of Veteran Affairs (VA).
The number of preliminary cases of GBS reported to VAERS among persons after they received the Janssen (Johnson & Johnson) COVID-19 vaccine was greater than the expected number of GBS cases. The reports were not limited to a specific age group, and there was no geographic clustering. The number of observed versus expected reports was not elevated for the mRNA COVID-19 vaccines.
Neither the VSD nor the VA data indicated that rates of GBS in the window following any of the COVID-19 vaccines differ from expected at this time; however, in VSD the rate of GBS following Janssen COVID-19 vaccine was higher than the rate following the mRNA vaccines.
GBS has been reported after receiving AstraZeneca COVID-19 vaccine, which is used in other countries. Both Janssen and AstraZeneca COVID-19 vaccines are adenovirus vector vaccines.
Review and adjudication of GBS case reports and diagnoses are underway in U.S. surveillance systems.
Ongoing monitoring of GBS among persons who received the Janssen COVID-19 vaccine in the United States is needed.
VaST will continue to review data on GBS after COVID-19 vaccination.Past reports from the VaST Work Group to ACIPVaST assessement of safety data
2022
February 4, 2022pdf icon
April 20, 2022pdf icon
May 19, 2022pdf icon2021
January 27, 2021pdf icon
March 1, 2021pdf icon
April 14, 2021pdf icon
April 23, 2021pdf icon
May 12, 2021pdf icon
June 23, 2021pdf icon
July 22, 2021pdf icon
August 30, 2021pdf icon
September 22, 2021pdf icon
October 21, 2021pdf icon
November 19, 2021pdf icon
December 16, 2021pdf icon
							
					
						Page last reviewed:  July 12, 2021					Content source: 	National Center for Immunization and Respiratory Diseases homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue